Safety of long acting insulin analogues discussed from the IGF-I receptor affinity

GAO Yan

DOI: https://doi.org/10.3969/j.issn.1006-6187.2012.06.020

2012-01-01

Abstract:It has been postulated that certain insulin analogues may display increased mitogenic potential and promote the growth of some cancers through binding to IGF-I receptors.We reviewed recent literatures which made investigations on the IGF-I receptor affinity and mitogenic potential of insulin analogues,and the risk of malignant neoplasms in diabetic patients treated with insulin analogues.In the in vitro studies,long acting insulin analogues were found to have similar IGF-I receptor affinity with human insulin in non-malignant cells but have greater mitogenic potential in some malignant cell lines.However,the in vitro studies showed that these are irrelevant to clinical practice because insulin analogues molecule is transformed rapidly once injected.Insulin detemir binds to albumin rapidly,and acts in the form of albumin-bound protein in vivo.While most abundant circulating form of insulin glargine is metabolite M1,which shows decreased mitogenic potential compared with human insulin.Clinical study about diabetic retinopathy suggests that insulin glargine does not increase IGF-I receptor affinity in vivo.Furthermore,there is no increased risk of cancer from insulin glargine reported in the new clinical studies.In response,the Food and Drug Administration,American Diabetes Association,American Association of Clinical Endocrinologists,and European Association for the Study of Diabetes have formally stated that patients should continue to follow the recommendations in the drug label to take insulin glargine or consult physicians for instruction.